March 2, 2015

The Honorable Pete Olson U.S. House of Representatives 2133 Rayburn House Office Bldg. Washington, D.C. 20515 The Honorable David Loebsack U.S. House of Representatives 1527 Longworth House Office Bldg. Washington, D.C. 20515

Dear Representative Olson and Representative Loebsack,

The undersigned organizations, representing physicians, allied health professionals, patients, community health organizations and industry, write to thank you for introducing H.R. 1192, "The National Diabetes Clinical Care Commission Act," in the 114<sup>th</sup> Congress. As supporters of this legislation and its objectives, we look forward to working with you to achieve passage by the House of Representatives as soon as possible.

With your leadership regarding this very important piece of legislation, our nation puts forth a serious response to the escalating diabetes epidemic and the chronic diseases that represent complications of the disease. We know from the Centers for Disease Control (CDC) 2014 National Diabetes Statistics Report that the number of Americans with diabetes continues to grow unchecked. We also know that maintaining the status quo of care for the 86 million Americans with pre-diabetes is not an option.

H.R. 1192 creates a commission for the purpose of improving the implementation and coordination of clinical care for patients with pre-diabetes, diabetes and the chronic diseases and conditions that result from diabetes, such as cardiovascular disease, kidney disease, blindness and neuropathy. The Commission, representing a partnership between private sector experts and specialists in the Federal agencies most active in clinical care, will provide the mechanism to address this epidemic which touches 1 out of every 9 Americans over the age of 20 and threatens to bankrupt our healthcare system.

As you know, similar legislation introduced in the 113<sup>th</sup> Congress (H.R. 1074) had 183 bi-partisan cosponsors and we are working hard to exceed this number in the 114th Congress and have this legislation enacted. We appreciate your leadership on this critical healthcare issue and thank you on behalf of patients with diabetes and pre-diabetes and the constituencies that our organizations represent.

Sincerely,

Abbott

Academy of Nutrition and Dietetics
American Academy of Family Physicians
American Academy of Ophthalmology
American Association of Clinical Endocrinologists
American Association of Diabetes Educators
American Association of Kidney Patients
American Clinical Laboratory Association
American College of Cardiology
American Diabetes Association
American Medical Association
American Optometric Association
American Podiatric Medical Association

American Society for Metabolic and Bariatric Surgery American Society of Bariatric Physicians American Society of Nephrology

**Bayer Corporation** 

**Board for Certification of Nutrition Specialists** 

Boehringer Ingelheim

Dexcom, Inc.

Diabetes Hands Foundation

diaTribe Foundation

Eli Lilly and Company

**Endocrine Society** 

GlaxoSmithKline

Healthcare Leadership Council

**Health Monitor Network** 

Johnson & Johnson

Juvenile Diabetes Research Foundation

Lexicon Pharmaceuticals, Inc.

Medtronic

Merck

**National Kidney Foundation** 

Novo Nordisk

**Obesity Action Coalition** 

Omada Health, Inc.

Pediatric Endocrine Society

Renal Physicians Association

Results for Life

Roche Diagnostics Diabetes Care

The Obesity Society

Vivus, Inc.

**VSP Vision Care** 

YMCA of the USA